Fournier's Gangrene

1. Overview

Fournier's Gangrene is a fulminant, life-threatening necrotising fasciitis of the perineum, genitalia, and perianal region. First described by Jean Alfred Fournier in 1883, it represents a urological and surgical emergency characterised by polymicrobial synergistic infection leading to obliterative endarteritis of subcutaneous vessels and rapid, progressive tissue necrosis. [1,2]

The condition predominantly affects the scrotum and penis in males and the vulva in females, though spread can extend to the perineum, buttocks, and anterior abdominal wall via continuous fascial planes. The infection is typically polymicrobial, involving aerobic and anaerobic bacteria working synergistically to produce devastating local and systemic effects. [3]

Without immediate recognition and aggressive surgical intervention, mortality remains unacceptably high at 20-40%, with delays to surgery being the single most significant predictor of death. The condition demands a high index of suspicion, particularly in diabetic and immunocompromised patients presenting with perineal pain and systemic toxicity. "Time is tissue"

• every hour of delay increases morbidity and mortality. [4,5]

Key Clinical Facts

• Spare the Testes: The testes are almost always spared because their blood supply (testicular artery from the abdominal aorta) is anatomically separate from the scrotal skin and fascia (supplied by pudendal and scrotal branches). This anatomical principle is critical for understanding spread patterns. [6]

• Spread Velocity: The infection spreads along fascial planes (Dartos → Colles' → Scarpa's fascia) at a documented rate of 2-3 cm per hour in untreated cases. This explains why patients deteriorate so rapidly. [7]

• Diabetes Dominance: Diabetes mellitus is the single most important risk factor, present in 60-80% of cases. Hyperglycaemia impairs neutrophil function, promotes bacterial growth, and causes microvascular disease, creating the perfect environment for infection. [8,9]

Clinical Pearls

Pain Out of Proportion: This is the pathognomonic hallmark of necrotising fasciitis. The patient experiences excruciating pain that seems disproportionate to the relatively benign-appearing skin changes initially. This occurs because the necrosis begins in the deep fascia and subcutaneous tissues before becoming visible on the skin surface. By the time skin changes are obvious, extensive deep tissue destruction has occurred. [10]

The "Finger Test" (Bedside Incision): When clinical suspicion is high but diagnosis uncertain, perform a bedside incision under local anaesthetic. In necrotising fasciitis, the finger passes easily along the fascial plane without normal resistance (due to enzymatic lysis of fascial attachments) and expresses characteristic "dishwater pus"

• thin, grey, foul-smelling fluid. This positive finding mandates immediate theatre. [11]

Don't Wait for the Scanner: If crepitus is palpable or frank gangrene is visible, proceed directly to theatre. CT scanning causes potentially fatal delays in unstable patients. Imaging should only be performed in stable patients where diagnosis remains uncertain or to delineate extent of spread for surgical planning. [12]

---

2. Epidemiology

Incidence and Prevalence

Fournier's Gangrene is a rare condition with an estimated incidence of 1.6-3 cases per 100,000 males annually. The condition shows geographic variation, with higher rates reported in developing countries and tropical climates where hygiene standards may be lower and diabetes prevalence is rising. [13,14]

Demographics

• Gender: Overwhelmingly affects males (male:female ratio 10:1). The male predominance reflects anatomical vulnerability - the longer urogenital tract in males provides more potential portals of entry, and the scrotal skin is more susceptible to minor trauma. [15]

• Age: Peak incidence occurs in the 6th and 7th decades of life, correlating with increased prevalence of diabetes, vascular disease, and immunosuppression in this age group. Cases in younger patients are almost always associated with HIV/AIDS, immunosuppressive therapy, or injection drug use. [16]

• Ethnicity: Some studies suggest higher rates in African and Hispanic populations, though this likely reflects socioeconomic factors and diabetes prevalence rather than genetic predisposition. [18]

Risk Factors

Risk factors create an environment conducive to infection through immunosuppression, microvascular disease, or providing a portal of entry:

Metabolic/Systemic Conditions (60-90% of cases)

• Diabetes Mellitus (60-80%): Hyperglycaemia impairs neutrophil chemotaxis, phagocytosis, and intracellular killing. Diabetic microangiopathy reduces tissue perfusion. [8,9]
• Alcoholism (25-50%): Causes immunosuppression, malnutrition, and poor hygiene. Often coexists with diabetes. [19]
• Obesity: Creates skin folds that trap moisture and bacteria, and is associated with diabetes and impaired wound healing. [20]
• Malignancy: Particularly haematological malignancies causing neutropenia. [21]

Immunosuppression

• HIV/AIDS (CD4 less than 200): Profoundly impaired cellular immunity. [22]
• Corticosteroid therapy: Impairs both innate and adaptive immunity.
• Chemotherapy: Causes neutropenia and mucositis (potential portal).
• Solid organ transplantation: Multiple immunosuppressive agents.

Local/Anatomical Factors (Portal of Entry)

• Perianal abscess/fistula (30-50%): Colorectal source introduces bowel flora. [23]
• Urethral stricture/instrumentation: Urological procedures, catheterisation, cystoscopy. [24]
• Genital trauma: Including sexual activity, shaving, piercing.
• Skin infections: Folliculitis, hidradenitis suppurativa, carbuncles.
• Recent surgery: Haemorrhoidectomy, circumcision, hernia repair. [25]

Vascular Disease

• Peripheral vascular disease: Reduces tissue perfusion and immune cell delivery.
• Chronic kidney disease: Uraemia impairs neutrophil function. [26]

---

3. Aetiology and Pathophysiology

Microbiology

Fournier's Gangrene is almost always polymicrobial (> 90% of cases), with an average of 4-5 bacterial species isolated per patient. The synergistic interaction between aerobic and anaerobic organisms is central to pathogenesis. [27,28]

Aerobic Organisms (60-80% of isolates)

• Escherichia coli (most common overall)
• Klebsiella pneumoniae
• Enterococcus faecalis
• Pseudomonas aeruginosa
• Staphylococcus aureus (including MRSA)
• Streptococcus species (including Group A β-haemolytic strep)

Anaerobic Organisms (80-90% of cases)

• Bacteroides fragilis (most common anaerobe)
• Clostridium species (produces gas and toxins)
• Peptostreptococcus
• Prevotella
• Fusobacterium

Fungal Organisms (Rare)

• Candida albicans - seen in immunocompromised hosts

The source of infection determines the microbiological profile:

• Colorectal source (perianal abscess/fistula): Mixed bowel flora with high anaerobic burden [23]
• Urological source (UTI, catheter): Gram-negative rods, Enterococcus [24]
• Cutaneous source (trauma, folliculitis): Staphylococcus, Streptococcus [29]

Pathophysiological Mechanism

The disease progression follows a devastating cascade:

1. Inoculation and Portal of Entry Bacteria enter the subcutaneous tissue through a breach in the skin or mucosa. In 20-30% of cases, no obvious portal can be identified ("idiopathic"), though microscopic trauma or transient bacteraemia is presumed. [30]

2. Aerobic-Anaerobic Synergy This is the cornerstone of pathogenesis:

• Aerobic bacteria (E. coli, Klebsiella) proliferate first, consuming available oxygen and creating a hypoxic environment
• Anaerobic bacteria (Bacteroides, Clostridium) then thrive in the oxygen-depleted tissue
• Anaerobes produce hydrogen and nitrogen gas → subcutaneous emphysema and crepitus
• Both produce synergistic toxins and enzymes [27,28]

3. Enzymatic Tissue Destruction Bacteria produce tissue-destroying enzymes:

• Collagenases: Destroy collagen in fascia and blood vessel walls
• Hyaluronidases: Break down hyaluronic acid in connective tissue matrix, facilitating spread
• Lipases: Destroy cell membranes
• Proteases: Digest structural proteins [31]

These enzymes liquefy the fascial planes, allowing rapid bacterial spread along paths of least resistance (Dartos → Colles' → Scarpa's fascia).

4. Obliterative Endarteritis and Thrombosis Bacterial endotoxins and exotoxins cause:

• Endothelial damage to small nutrient vessels
• Thrombosis of subcutaneous arterioles and venules
• Tissue ischaemia progressing to necrosis
• Formation of characteristic gangrenous eschar [32]

The skin necrosis is therefore a secondary event - by the time it appears, extensive deep tissue destruction has already occurred.

5. Systemic Toxicity

• Endotoxin release (Gram-negative bacteria): Triggers systemic inflammatory response syndrome (SIRS)
• Exotoxins (Streptococcus, Clostridium): Cause remote organ damage
• Cytokine storm: Massive release of TNF-α, IL-1, IL-6 → septic shock, multi-organ failure [33]

Anatomical Spread Patterns

Understanding fascial anatomy is critical to predicting spread:

Male Perineum and Genitalia

1. Dartos fascia (scrotum): Continuous with
2. Colles' fascia (perineum): Continuous with
3. Scarpa's fascia (anterior abdominal wall)

Infection can spread from scrotum → perineum → abdominal wall up to the level of the clavicles (limited only by fusion of Scarpa's fascia with fascia lata of thigh).

Female Perineum Similar fascial continuity exists, allowing vulvar infection to spread to perineum and abdominal wall. [34]

Posterior Spread Perianal source can spread:

• Laterally to ischiorectal fossae
• Posteriorly to gluteal region
• Anteriorly to perineum and genitalia

Critical Anatomical Sparing

• Testes: Spared because testicular artery arises from aorta and descends in spermatic cord, separate from scrotal fascial planes [6]
• Glans penis: Spared because Buck's fascia (deep fascia of penis) is not continuous with Dartos/Colles' fascia
• Bone and muscle: Deep fascia forms a barrier (unless directly involved by trauma)

---

4. Clinical Presentation

Symptom Onset and Progression

The clinical course typically evolves over 2-7 days, though fulminant progression over 12-24 hours can occur, particularly in immunocompromised hosts. Early recognition requires high clinical suspicion. [35]

Symptoms

Early Symptoms (First 24-48 hours)

• Perineal/scrotal/vulvar pain: Constant, severe, progressively worsening
• "Pain out of proportion": The hallmark symptom - pain severity exceeds apparent skin changes
• Pruritus: Intense itching may precede pain
• Swelling: Rapidly progressive oedema of genitalia

Progressive Symptoms (48-72 hours)

• Systemic toxicity: Fever, rigors, malaise
• Urinary symptoms: Dysuria, retention (if urethral source)
• Altered mental status: Confusion, delirium (septic encephalopathy)

Late Symptoms (> 72 hours, untreated)

• Septic shock: Hypotension, oliguria, multi-organ dysfunction
• Inability to walk: Due to pain and leg oedema
• Faecal/urinary incontinence: If sphincter involvement

Signs

Cutaneous Changes (Progressive Sequence)

1. Erythema: Spreading, poorly demarcated, warm
2. Oedema: "Woody" induration, non-pitting
3. Skin colour changes:
   • Purple/dusky patches (early ischaemia)
   • Dark blue/black areas (established necrosis)
   • Bullae (fluid-filled blisters, often haemorrhagic)
4. Gangrene: Black leathery eschar (full-thickness necrosis)
5. Skin sloughing: Skin falls off with gentle traction (very late)

Pathognomonic Signs

• Crepitus: "Rice Krispies" crunching sensation on palpation, due to subcutaneous gas. Present in 30-60% of cases. Highly specific but not sensitive. [36]
• Dishwater pus: Thin, grey, turbid, foul-smelling discharge
• Distinctive odour: Putrid, "rotten flesh" smell often noticeable on entering the room

Systemic Signs

• Fever: Temperature > 38.5°C (though hypothermia in severe sepsis)
• Tachycardia: > 100 bpm
• Hypotension: less than 90 mmHg systolic (late sign, indicates shock)
• Tachypnoea: > 20 breaths/min
• Altered consciousness: Confusion, agitation, reduced GCS

Extent Assessment

• Extent often greater than apparent on inspection - "iceberg" phenomenon
• Gentle palpation to assess boundaries (avoid aggressive examination)
• Assess for spread: buttocks, thighs, abdominal wall

---

5. Clinical Examination

Systematic Approach

General Inspection

• Appearance: Toxic, distressed, in obvious pain
• Position: May be unable to lie flat or move legs
• Odour: Note any distinctive smell

Vital Signs

• Temperature, heart rate, BP, respiratory rate, oxygen saturations
• Calculate Early Warning Score (NEWS2)

Focused Perineal Examination Examine with patient in lithotomy or frog-leg position. Ensure adequate light and exposure.

Inspection

• Skin changes (erythema, oedema, necrosis, bullae)
• Anatomical extent (scrotum, penis, perineum, buttocks, abdominal wall)
• Discharge or purulent exudate
• Obvious portal of entry (wound, abscess)

Palpation (Gentle - avoid causing further trauma)

• Crepitus: Subcutaneous gas
• Fluctuance: Suggests abscess
• Tenderness: Extent of tender area often exceeds visible changes
• "Wooden" induration: Firm, non-pitting oedema

Digital Rectal Examination (Mandatory)

• Assess for perianal abscess (boggy, tender swelling)
• Palpate for anal fistula
• Check sphincter tone
• Assess rectal mucosa

Urological Assessment

• Testes: Palpable? Tender? (Usually spared)
• Urethral meatus: Discharge? Stricture?
• Bladder: Palpable? (Retention)
• Inguinal nodes: Lymphadenopathy

Abdominal Examination

• Assess for peritonitis (suggests bowel perforation)
• Palpate for abdominal wall involvement

Vascular Assessment

• Peripheral pulses (assess perfusion and vascular disease)
• Capillary refill time

Documentation

Use standardised documentation including:

• Detailed description of affected area
• Photographic documentation (with consent)
• Marking extent with pen (to monitor progression)
• Time-stamped assessment

---

6. Differential Diagnosis

The key challenge is distinguishing Fournier's Gangrene from more benign scrotal/perineal conditions. When in doubt, assume necrotising fasciitis and escalate urgently.

Critical Differentials ("Must Not Miss")

1. Necrotising Fasciitis (Other Sites)

• May affect limbs, abdominal wall, etc.
• Same pathophysiology, different anatomical site
• Management principles identical [10]

2. Fournier's vs Simple Cellulitis This is the most common diagnostic dilemma.

Common Differentials

3. Scrotal Abscess

• Localized fluctuant collection
• No crepitus or spreading necrosis
• May progress to Fournier's if untreated
• Incision and drainage often sufficient [37]

4. Epididymo-orchitis

• Pain localized to epididymis/testis
• Scrotal skin relatively spared
• Positive urine culture
• Responds to antibiotics alone [38]

5. Testicular Torsion

• Sudden onset severe testicular pain
• Absent cremasteric reflex
• High-riding testis
• Ultrasound shows absent flow
• Requires urgent surgical exploration [39]

6. Strangulated Inguinoscrotal Hernia

• History of reducible hernia
• Bowel obstruction symptoms
• Palpable bowel/omentum in scrotum
• No crepitus or systemic sepsis [40]

7. Perianal Abscess (Simple)

• Localized perianal swelling and pain
• Fluctuant, well-demarcated
• No extensive skin necrosis
• I&D curative [41]

Diagnostic Approach

High Suspicion (Immediate Surgery) if:

• Pain out of proportion + any skin change
• Crepitus
• Systemic sepsis with perineal pathology
• Rapid progression documented

Moderate Suspicion (Urgent Investigation) if:

• Diabetic/immunocompromised + perineal pain
• Unexplained fever + genital symptoms
• Recent instrumentation + deterioration

Lower Suspicion but Monitor if:

• Localized symptoms only
• No systemic features
• Clear alternative diagnosis (e.g., epididymitis)
• BUT: Reassess frequently (4-6 hourly)

---

7. Investigations

Guiding Principle

Do not delay surgery for investigations in clinically obvious cases. If diagnosis is clear (crepitus, necrosis, systemic sepsis), proceed directly to theatre. Investigations are for:

1. Stable patients where diagnosis is uncertain
2. Assessing extent of disease for surgical planning
3. Identifying complications and guiding resuscitation

Bedside Investigations

1. Finger Test (Bedside Incision)

• Perform under local anaesthetic if diagnosis uncertain
• Make 2cm incision down to fascia
• Positive findings (confirms necrotising fasciitis):
  • Finger dissects easily along fascial plane without resistance
  • "Dishwater pus" expression (grey, thin, foul)
  • Lack of bleeding (due to thrombosed vessels)
  • Necrotic fascia visible
• Negative findings: Normal tissue resistance, minimal pus, viable tissue
• If positive → immediate theatre [11]

2. Urinalysis and Urine Culture

• Identify urological source (UTI, urethral pathology)
• Pyuria, bacteriuria common [24]

Laboratory Investigations

Essential Bloods (STAT)

LRINEC Score (Laboratory Risk Indicator for Necrotising Fasciitis)

Developed by Wong et al. (2004) to aid early diagnosis: [42]

Interpretation:

• ≤5 points: Low risk (less than 50% probability)
• 6-7 points: Intermediate risk
• ≥8 points: High risk (> 75% probability)

CRITICAL LIMITATION: A low LRINEC score does NOT exclude necrotising fasciitis. Up to 25% of proven cases score less than 6. Clinical suspicion trumps scoring systems. [43]

Microbiological Investigations

1. Tissue Cultures (Intraoperative)

• Obtain deep tissue (not superficial swabs)
• Request aerobic and anaerobic cultures
• Fungal cultures if immunocompromised
• Gram stain (immediate guidance)

2. Blood Cultures

• Take 2 sets (aerobic and anaerobic bottles)
• Prior to antibiotics if possible
• Positive in 30-60% [27]

Imaging

1. Plain X-Ray (Scrotum/Perineum AP)

• Fast, bedside
• Detects subcutaneous gas (radiolucent streaks)
• Sensitivity only 25-50% (many cases have no gas) [44]
• Normal X-ray does NOT exclude diagnosis

2. Ultrasound

• Can show:
  • Scrotal wall thickening (> 8mm)
  • Fluid collections
  • Subcutaneous gas ("dirty shadowing")
• Advantage: Bedside, no radiation
• Limitation: Operator-dependent, poor sensitivity for gas [45]

3. CT Pelvis with IV Contrast (Gold Standard Imaging)

Indications:

• Stable patient with uncertain diagnosis
• Assess extent of spread for surgical planning
• Identify source (e.g., perirectal abscess, colovesical fistula)

Findings:

• Subcutaneous gas (pathognomonic): Linear or bubbling air pockets [46]
• Fascial thickening and oedema
• Asymmetric fat stranding
• Fluid collections/abscesses
• Lack of contrast enhancement (thrombosed vessels, necrosis)

Sensitivity/Specificity: 90%/80% for necrotising fasciitis [47]

CRITICAL WARNING: Do NOT delay surgery for CT in unstable patients or clinically obvious cases. "Door to OR" time is more important than imaging. [12]

4. MRI

• Superior soft tissue detail
• Detects early fascial involvement
• Limitation: Time-consuming, requires stable patient
• Rarely used in acute setting

---

8. Classification and Scoring Systems

Fournier's Gangrene Severity Index (FGSI)

Developed by Laor et al. (1995) to predict mortality. Uses physiological parameters at admission. [48]

Parameters Assessed:

• Temperature
• Heart rate
• Respiratory rate
• Serum sodium
• Serum potassium
• Serum creatinine
• Serum bicarbonate
• Haematocrit
• White blood cell count

Each parameter scored 0-4 based on degree of derangement. Total score 0-53.

Interpretation:

• Score less than 9: Mortality 25%
• Score 9-12: Mortality 50%
• Score > 12: Mortality 75%

Limitation: Does not account for extent of disease or timing of surgery. [49]

Uludag FGSI (uFGSI)

Modified scoring system adding:

• Age
• Extent of disease (localized vs disseminated)

Improved prognostic accuracy compared to original FGSI. [50]

Anatomical Classification

By Site of Origin:

1. Urogenital source (40-60%): UTI, urethral stricture, catheterisation [24]
2. Colorectal source (30-50%): Perianal abscess, fistula, diverticulitis [23]
3. Cutaneous source (10-20%): Trauma, folliculitis, hidradenitis [29]
4. Idiopathic (10-30%): No identifiable source [30]

By Extent:

• Localized: Confined to scrotum/perineum
• Regional: Extension to thighs, buttocks, or abdominal wall
• Extensive: Involvement beyond inguinal ligament or multiple regions

---

9. Management

Fundamental Principles

1. Resuscitation: Aggressive fluid resuscitation and organ support
2. Antibiotics: Broad-spectrum, high-dose, immediate
3. Surgery: Emergency radical debridement - THE definitive treatment
4. Repeated debridement: Planned return to theatre
5. Critical care: ICU-level support for septic shock

Timeline Critical Points

• Door to antibiotics: less than 1 hour (Surviving Sepsis Campaign) [51]
• Door to OR: less than 6 hours (ideal less than 3 hours) [17]
• Re-look surgery: 24-48 hours after initial debridement [52]

---

1. Initial Resuscitation (Sepsis Six - First Hour)

Three IN:

1. High-flow oxygen: Target SpO₂ 94-98% (or 88-92% if COPD risk)
2. IV fluid resuscitation:
   • Crystalloid bolus 500ml over 15 minutes
   • Reassess and repeat (target 30ml/kg in first 3 hours)
   • Guided by BP, urine output, lactate
3. IV antibiotics: Broad-spectrum (see below) - STAT dose

Three OUT:

1. Blood cultures: Before antibiotics if possible (but don't delay)
2. Measure lactate: Marker of tissue perfusion
3. Measure urine output: Catheterize, target > 0.5ml/kg/hr

Additional Resuscitation Measures:

• Vasopressors (noradrenaline): If fluid-refractory hypotension (MAP less than 65 mmHg despite fluids)
• Correct coagulopathy: FFP, platelets if DIC
• Tight glycaemic control: Insulin infusion (target 6-10 mmol/L) [53]

---

2. Antibiotic Therapy

Principle: Empirical broad-spectrum coverage for polymicrobial infection (aerobes, anaerobes, Gram-positive, Gram-negative). Start immediately - every hour of delay increases mortality. [54]

Recommended Empirical Regimen (Adult)

TRIPLE THERAPY:

1. Carbapenem: Meropenem 1g IV 8-hourly OR Imipenem 500mg IV 6-hourly

   • Covers: Gram-negative rods, many anaerobes
   • Alternative: Piperacillin-tazobactam 4.5g IV 6-hourly (but less anaerobic coverage)

2. Anti-MRSA: Vancomycin 15-20mg/kg IV loading dose, then 15-20mg/kg 12-hourly (dose adjust for renal function)

   • Covers: MRSA, Enterococcus
   • Alternative: Linezolid 600mg IV 12-hourly
   • Rationale: MRSA present in up to 30% of cases [55]

3. Protein Synthesis Inhibitor: Clindamycin 600-900mg IV 8-hourly

   • Critical role: Inhibits bacterial toxin production
   • Works regardless of bacterial growth phase
   • Synergistic with β-lactams [56]

Rationale for Clindamycin (The "Eagle Effect"): β-lactam antibiotics (penicillins, carbapenems) kill bacteria by disrupting cell wall synthesis during active division. In high bacterial load (as in necrotising fasciitis), bacteria enter stationary phase and stop dividing, making β-lactams less effective. Clindamycin inhibits ribosomal protein synthesis regardless of growth phase and, critically, stops production of exotoxins (e.g., Streptococcal pyrogenic exotoxins, Clostridial toxins). [57]

Alternative Regimens

If Penicillin Allergy:

• Ciprofloxacin 400mg IV 12-hourly + Metronidazole 500mg IV 8-hourly + Vancomycin

If Renal Impairment:

• Adjust doses of meropenem, vancomycin based on creatinine clearance
• Consider gentamicin dose monitoring

Antifungal Addition: Add Fluconazole 400mg IV daily OR Caspofungin 70mg loading, then 50mg daily if:

• Immunocompromised (HIV, transplant, chemotherapy)
• Candida isolated from cultures
• Failure to improve despite adequate bacterial coverage [58]

Duration of Therapy

• Continue IV antibiotics until:
  • Clinical improvement (defervescence, reducing inflammatory markers)
  • Completion of all debridement procedures
  • Healthy granulation tissue present
• Typical duration: 7-14 days IV, then step down to oral if appropriate [59]

De-escalation

• Tailor antibiotics once culture results available
• Narrow spectrum if specific organisms identified
• Continue anaerobic coverage until wound healing established

---

3. Surgical Management - Radical Debridement

Surgery is the definitive, life-saving treatment. Antibiotics alone are insufficient - necrotic tissue has no blood supply, so antibiotics cannot penetrate. Only complete excision of dead tissue achieves source control. [60]

Timing

• EMERGENCY surgery - same urgency as ruptured AAA or perforated viscus
• Target: less than 6 hours from diagnosis (ideally less than 3 hours) [17]
• Do NOT delay for:
  • Further imaging
  • ICU bed availability (debride in ED/Recovery if needed)
  • "Optimization" (resuscitation continues intraoperatively)

Anaesthetic Considerations

• General anaesthesia with endotracheal intubation
• Anticipate difficult resuscitation (vasopressors, invasive monitoring)
• Insert arterial line, central line
• Spinal/epidural contraindicated (risk of epidural abscess, coagulopathy) [61]

Surgical Principles

"When in doubt, cut it out"

1. Wide excision of ALL necrotic tissue

   • Excise until healthy, bleeding, viable tissue reached
   • Extends well beyond visible skin changes (often 2-3x visible area)
   • Positive "endpoint": Bright red bleeding from muscle, viable fascial edges

2. Preserve critical structures

   • Testes: Almost always viable - preserve and leave in situ or create scrotal pouch
   • Spermatic cord: Preserve unless directly involved
   • Urethra: Preserve if possible; may need suprapubic catheter if damaged
   • Penis glans and corpora: Usually spared (Buck's fascia barrier)

3. Leave wounds OPEN

   • Primary closure is contraindicated (causes abscess, recurrence)
   • Pack loosely with saline-soaked gauze
   • Allow drainage and ongoing assessment

4. Assess extent systematically:

   • Scrotum
   • Penis
   • Perineum
   • Perianal region
   • Buttocks
   • Medial thighs
   • Abdominal wall (up to umbilicus or beyond)

5. Source control:

   • Drain abscesses
   • Debride fistula tracts
   • Consider diverting colostomy if:
     • Perianal source with faecal contamination
     • Extensive perineal debridement
     • Sphincter involvement [62]

Specific Surgical Scenarios

Scrotal Involvement:

• Excise necrotic scrotal skin
• Testes usually viable - leave exposed or create thigh pouches
• Dartos muscle often necrotic - excise

Penile Involvement:

• Skin and superficial fascia may be necrotic
• Corpora cavernosa and urethra usually spared
• Preserve glans penis if viable
• May need circumferential degloving

Abdominal Wall Extension:

• May require excision up to costal margin
• Eventual reconstruction complex (flaps, grafts)

Perianal Source:

• Drain perianal/ischiorectal abscesses
• Colostomy indications:
  • Severe perianal involvement
  • Sphincter damage
  • Persistent faecal contamination
  • Rectovaginal/rectourethral fistula [63]

Intraoperative Findings Documentation

• Photograph (consent obtained preoperatively)
• Detailed operative note describing extent
• Microbiology samples (tissue, not swabs)
• Frozen section if malignancy suspected (rare)

---

4. Post-Operative ICU Management

All patients require critical care monitoring for at least 48-72 hours post-operatively.

Organ Support:

• Ventilation: Many patients require mechanical ventilation for 24-48h
• Vasopressors: Noradrenaline for septic shock (target MAP > 65 mmHg)
• Renal replacement therapy: If AKI with oliguria/anuria
• Nutrition: Early enteral feeding (NG tube) - high protein requirements [64]

Monitoring:

• Continuous ECG, BP (arterial line), SpO₂
• Hourly urine output (catheter)
• 4-hourly lactate, glucose, ABG
• Daily FBC, U&E, CRP, coagulation

Complications to Anticipate:

• Septic shock: May worsen post-op (bacterial toxin release during surgery)
• DIC: Monitor coagulation, platelets
• AKI: Commonest organ failure
• ARDS: Mechanical ventilation may be prolonged
• Hyperglycaemia: Tight control with insulin infusion

---

5. Planned Re-Look Surgery

Scheduled return to theatre in 24-48 hours is MANDATORY, even if patient appears improved. [52]

Rationale:

• Necrosis progresses despite initial debridement
• Demarcation of viable/non-viable tissue becomes clearer
• Further debridement almost always needed

Frequency:

• Every 24-48 hours until:
  • No further necrotic tissue
  • Healthy granulation tissue present
  • No signs of ongoing infection

Average number of debridements: 3-5 procedures [65]

Endpoints for Cessation:

• Clean, healthy-appearing wounds
• Granulation tissue formation
• Falling inflammatory markers (CRP, WCC)
• Clinical improvement (defervescence, haemodynamic stability)

---

6. Wound Management

Acute Phase (Days 1-14):

• Negative pressure wound therapy (VAC dressing):
  • Promotes granulation tissue
  • Reduces oedema
  • Prepares wound bed for reconstruction
  • Apply at 2nd or 3rd debridement once wound stable [66]
• Honey-impregnated dressings: Antimicrobial properties
• Daily dressing changes initially

Subacute Phase (Weeks 2-6):

• Continue VAC therapy
• Wound contraction begins
• Granulation tissue fills defect
• Consider hyperbaric oxygen (controversial - see below)

Reconstruction Phase (Weeks 4-12): Timing depends on wound readiness and patient stability.

Options:

1. Secondary intention healing: Small defects (less than 5cm), acceptable cosmesis
2. Split-thickness skin grafts (STSG): Most common
   • Meshed graft allows drainage
   • Harvest from thigh
   • Good take on healthy granulation tissue [67]
3. Flaps (if large defect, exposed vital structures):
   • Gracilis muscle flap (medial thigh)
   • Rectus abdominis flap (abdominal wall)
   • Scrotal reconstruction: thigh pouches, STSG, or local flaps [68]
4. Testicular placement:
   • Subcutaneous thigh pouches (temporary)
   • Scrotal reconstruction (skin graft to dartos remnant)

Reconstructive Goals:

• Functional: Urinary/sexual function, mobility
• Cosmetic: Acceptable appearance, patient satisfaction
• Often requires multiple staged procedures

---

7. Adjunctive Therapies

Hyperbaric Oxygen Therapy (HBOT)

Theoretical Benefits:

• Increases tissue oxygen tension → inhibits anaerobic bacteria
• Enhances neutrophil killing
• Promotes angiogenesis and wound healing
• Reduces oedema [69]

Evidence:

• No high-quality RCTs demonstrating mortality benefit
• Some observational studies suggest fewer debridements, shorter hospital stay [70]
• Problem: Logistical difficulty (need hyperbaric chamber, patient transport)
• Delays definitive surgery if prioritised

Current Consensus:

• May be considered as adjunct (not replacement) to surgery
• Only in stable patients post-debridement
• Not recommended if delays surgery or ICU care [71]

IVIG (Intravenous Immunoglobulin)

Indication:

• Streptococcal toxic shock syndrome (specifically Group A Streptococcus)
• Neutralizes streptococcal superantigens

Dose:

• 2g/kg as single dose over 24 hours

Evidence:

• Observational data suggests benefit in streptococcal necrotising fasciitis with toxic shock [72]
• Not routinely indicated unless GAS confirmed

---

10. Complications

Fournier's Gangrene carries devastating morbidity even in survivors.

Early Complications (Days 0-7)

Intermediate Complications (Weeks 1-4)

Late Complications (Months to Years)

Mortality

Overall mortality: 20-40% (despite treatment) [4,5]

Factors Associated with Increased Mortality:

• Age > 60 years
• Extensive disease (> 5% body surface area)
• Delay to surgery (> 24 hours)
• FGSI score > 9
• Serum lactate > 4 mmol/L
• Septic shock requiring vasopressors
• Renal failure requiring dialysis
• Immunosuppression (HIV, malignancy) [80]

---

11. Prognosis and Outcomes

Survival Outcomes

With prompt treatment:

• Mortality: 20-40%
• Survivors have prolonged hospital stay: 30-60 days average [81]
• Multiple surgeries required: Average 3-5 debridements [65]

Delayed treatment (> 24 hours to surgery):

• Mortality: 40-80% [17]

Functional Outcomes

Urological Function:

• Urethral stricture: 10-30% require dilation or urethroplasty [77]
• Erectile dysfunction: 30-50% (multifactorial - organic, psychogenic, vascular) [78]

Cosmetic Outcomes:

• Most patients require skin grafting
• Scrotal reconstruction achieves acceptable appearance in 70-80% [68]
• Patient satisfaction variable (depends on expectations, sexual function)

Quality of Life:

• Significantly impaired in first year
• Gradual improvement but rarely returns to baseline
• Depression common (30-40%) [82]
• Sexual dysfunction impacts relationships

Factors Predicting Good Outcome

• Young age (less than 50 years)
• Absence of diabetes/immunosuppression
• Localized disease
• Early surgery (less than 12 hours)
• Low FGSI score (less than 9)
• Single organism on culture
• No organ failure

---

12. Prevention and Screening

Primary Prevention

In At-Risk Populations (Diabetics, Immunocompromised):

• Strict glycaemic control: HbA1c less than 7% [83]
• Perineal hygiene education: Daily washing, dry carefully
• Prompt treatment of minor infections: Folliculitis, abscesses
• Avoid instrumentation if possible: Catheterisation only when necessary
• Treat urological/colorectal pathology: Strictures, fistulas, abscesses [84]

Post-Operative Prevention (Perineal Surgery):

• Prophylactic antibiotics (colorectal surgery, urological procedures)
• Meticulous surgical technique
• Wound care education

Secondary Prevention (Early Detection)

High-Risk Patient Education: Counsel diabetics, immunocompromised patients to seek immediate care if:

• Perineal/genital pain and swelling
• Fever with urinary/perianal symptoms
• Any rapidly progressive skin changes

Healthcare Provider Education:

• High index of suspicion in diabetics with perineal symptoms
• Avoid dismissing as "simple cellulitis"
• Early surgical consultation

No Formal Screening Programs

• Too rare to justify population screening
• Unpredictable onset in most cases

---

13. Key Guidelines and Evidence

Major Society Guidelines

Landmark Studies

1. Wong et al. (2004) - LRINEC Score Development

• Developed laboratory-based scoring system to aid early diagnosis
• Validated in 314 patients with soft tissue infections
• Limitations: Sensitivity only 68%, cannot rule out diagnosis
• Citation: Critical Care Medicine 2004;32(7):1535-1541 [42]

2. Laor et al. (1995) - FGSI Prognostic Score

• First validated severity scoring system for Fournier's
• Demonstrated FGSI > 9 associated with 75% mortality
• Guides prognostic counselling
• Citation: British Journal of Urology 1995;76(1):81-85 [48]

3. Sorensen et al. (2009) - Time to Surgery and Mortality

• Large retrospective analysis (1,726 patients)
• Demonstrated each 24-hour delay to surgery associated with doubling of mortality
• Strong evidence for emergency surgical approach
• Citation: European Urology 2009;55(4):945-954 [17]

4. Chennamsetty et al. (2015) - HBOT Meta-Analysis

• Systematic review of hyperbaric oxygen as adjunct
• No mortality benefit demonstrated
• May reduce number of debridements (low-quality evidence)
• Citation: Canadian Urological Association Journal 2015;9(1-2):E72-E77 [70]

Key Evidence Points

Antibiotic Timing:

• Each hour delay to antibiotics increases mortality by 7.6% in septic shock [86]
• Supports immediate empirical therapy

Surgical Timing:

• Mortality 7.7% if surgery less than 24h vs 38% if > 24h [17]
• Strongest modifiable risk factor

Colostomy:

• Reduces wound contamination, may reduce mortality in colorectal source [62]
• Not universally required

---

14. Patient and Layperson Explanation

What is Fournier's Gangrene?

Fournier's Gangrene is a severe, rapidly spreading infection of the private parts (genitals and perineum - the area between the genitals and anus). "Gangrene" means the tissue dies. This condition is a medical emergency requiring immediate hospital treatment, including surgery.

How does it happen?

Bacteria (germs) enter the skin or deeper tissues, usually through a small cut, scratch, abscess, or after medical procedures. In healthy people, the immune system fights off these bacteria. However, if someone has diabetes, a weak immune system, or poor blood flow, the bacteria can multiply rapidly. They produce toxins and enzymes that destroy tissue and block blood vessels, causing the skin and deeper layers to die.

Who gets it?

It mainly affects:

• Men (9 out of 10 cases)
• People over 50 years old
• People with diabetes (present in 6-8 out of 10 cases)
• People with weakened immune systems (HIV, cancer treatment, organ transplant)
• People who drink alcohol heavily

What are the warning signs?

Early signs (see a doctor immediately):

• Severe pain in the genital or perineal area
• Pain that seems worse than the visible skin changes
• Swelling of the scrotum, penis, or labia
• Fever and feeling very unwell

Late signs (call 999/emergency services):

• Skin turning purple, blue, or black
• Blisters or broken skin
• Crackling feeling under the skin when touched
• Very foul smell
• Confusion or drowsiness
• Very low blood pressure (shock)

How serious is it?

This is a life-threatening emergency. Without surgery, it is almost always fatal. Even with the best treatment, 2-4 out of 10 people do not survive. Those who survive need extensive treatment and often have long-term problems.

What is the treatment?

1. Emergency surgery Surgeons must cut away all the dead and infected tissue. This often means removing large areas of skin and tissue from the scrotum, penis, perineum, or surrounding areas. The wound is left open (not stitched closed) to allow drainage and healing.

2. Antibiotics Strong intravenous (drip) antibiotics are given immediately to kill the bacteria.

3. Intensive care Most patients need to stay in intensive care for several days because the infection causes the body to go into shock (very low blood pressure, organ failure).

4. Multiple operations Patients usually need to return to the operating theatre every 1-2 days for several more operations to remove additional dead tissue and clean the wound.

5. Reconstruction Once the infection is controlled, skin grafts (transplanting skin from another part of the body) or other plastic surgery is needed to reconstruct the area. This may happen weeks to months later.

What is the recovery like?

• Hospital stay: Usually 4-8 weeks
• Number of operations: Typically 3-5, sometimes more
• Wound healing: Takes months
• Reconstruction: May require additional surgeries for appearance and function
• Psychological impact: Many people experience depression, anxiety, or PTSD
• Sexual function: May be affected, requiring specialist support

Can it be prevented?

If you have diabetes or a weak immune system:

• Keep blood sugar well controlled
• Keep the genital area clean and dry
• See a doctor promptly for any genital pain, swelling, or skin changes
• Treat minor infections (boils, cuts) early
• Attend regular check-ups

When to seek emergency help: If you have diabetes or a weak immune system and develop:

• Sudden severe genital or perineal pain
• Rapidly spreading redness or swelling
• Fever with genital symptoms
• Any skin colour changes (purple, black)

Don't wait - go to A&E (Emergency Department) immediately.

Questions to ask your doctor

1. What caused my infection?
2. How extensive is the tissue damage?
3. How many operations will I need?
4. What will my recovery look like?
5. Will I need plastic surgery later?
6. What support is available for coping emotionally?
7. How will this affect sexual function?

---

15. Examination Focus (FRCS/MRCS)

Common Exam Scenarios

1. Clinical Scenario (Viva/OSCE) "A 62-year-old man with diabetes presents to A&E with severe scrotal pain and swelling. On examination, there is dusky discolouration of the scrotum and crepitus. What is your diagnosis and immediate management?"

Model Answer: "This presentation is highly suggestive of Fournier's Gangrene - a necrotising fasciitis of the perineum and genitalia. This is a surgical emergency with high mortality. My immediate management would follow an ABC approach:

Resuscitation: I would initiate the Sepsis Six - give high-flow oxygen, obtain IV access and take blood cultures, administer broad-spectrum IV antibiotics (meropenem, vancomycin, and clindamycin), start IV fluid resuscitation, measure lactate, and catheterise to monitor urine output.

Antibiotics: I would start triple therapy immediately: meropenem 1g IV for Gram-negative and anaerobic cover, vancomycin for MRSA cover, and clindamycin for toxin suppression.

Surgery: This patient requires emergency radical surgical debridement. I would contact the on-call consultant surgeon immediately, inform anaesthetics and theatre, and aim for surgery within 6 hours, ideally within 3 hours.

Investigations: While preparing for theatre, I would send bloods including FBC, CRP, U&E, glucose, lactate, coagulation, and blood cultures. I would calculate a LRINEC score but would not delay surgery if clinical suspicion is high. CT pelvis may help delineate extent but should not delay surgery in an unstable patient.

Definitive management: Emergency radical debridement of all necrotic tissue until healthy bleeding tissue is encountered, leaving wounds open, with planned return to theatre in 24-48 hours for reassessment and further debridement if needed."

2. Anatomy Question "Why are the testes typically spared in Fournier's Gangrene?"

Answer: "The testes have a separate blood supply from the scrotal skin. The testicular arteries arise directly from the abdominal aorta below the renal arteries and descend through the inguinal canal in the spermatic cord. In contrast, the scrotal skin is supplied by the pudendal arteries and scrotal branches of the femoral artery. Fournier's gangrene spreads along the superficial fascial planes (Dartos, Colles', Scarpa's fascia) and causes thrombosis of the skin vessels, but the testicular vessels within the spermatic cord remain patent. Therefore, even with complete necrosis of scrotal skin, the testes themselves usually remain viable."

3. Pharmacology Question "What is the rationale for adding clindamycin to the antibiotic regimen in necrotising fasciitis?"

Answer: "Clindamycin has a unique and critical role. While beta-lactam antibiotics like meropenem work by disrupting bacterial cell wall synthesis during active division, in necrotising fasciitis there is a very high bacterial load (inoculum). In this high-inoculum state, bacteria enter stationary phase and stop dividing, making beta-lactams less effective - this is called the Eagle Effect.

Clindamycin is a protein synthesis inhibitor that works on bacterial ribosomes regardless of whether bacteria are actively dividing. More importantly, it suppresses bacterial toxin production - specifically exotoxins produced by Streptococcus and Clostridium species. These toxins cause much of the systemic toxicity and tissue damage. By inhibiting ribosomal function, clindamycin stops toxin synthesis, reducing systemic inflammatory response and tissue destruction.

Therefore, clindamycin is synergistic with beta-lactams and is an essential component of the antibiotic regimen."

4. Management Priority Question "A patient with suspected Fournier's gangrene is haemodynamically unstable. Should you obtain a CT scan before taking them to theatre?"

Answer: "No. In this scenario, clinical diagnosis is clear and the patient is unstable. CT scanning would cause a potentially fatal delay. The priority is emergency surgical debridement - this is the definitive treatment and source control. Imaging should only be performed in haemodynamically stable patients where the diagnosis is uncertain or to delineate extent for surgical planning. The principle is 'door to OR' rather than 'door to CT'. If crepitus is present, skin necrosis is visible, or the patient is septic with perineal pathology, theatre takes absolute priority."

Viva Opening Statements

Definition: "Fournier's Gangrene is a polymicrobial necrotising fasciitis of the perineum, genitalia, and perianal region, first described by Jean Alfred Fournier in 1883. It is characterized by synergistic bacterial infection causing obliterative endarteritis, rapid tissue necrosis, and high mortality."

Epidemiology Soundbite: "It affects predominantly males with a 10:1 ratio, peak age 50-70 years, with an incidence of approximately 1.6-3 per 100,000 males annually. Diabetes is present in 60-80% of cases and is the strongest risk factor. Overall mortality is 20-40% despite treatment, increasing to 40-80% if surgery is delayed beyond 24 hours."

Management Soundbite: "Management is a surgical emergency. The three pillars are: (1) Aggressive resuscitation and broad-spectrum antibiotics - meropenem, vancomycin, and clindamycin; (2) Emergency radical surgical debridement of all necrotic tissue within 6 hours; and (3) Planned return to theatre every 24-48 hours for further debridement until healthy granulation tissue is achieved."

Common Mistakes in Exams

❌ Calling it "cellulitis" and planning conservative management

• Fournier's is a surgical emergency; antibiotics alone are inadequate

❌ Forgetting clindamycin in antibiotic regimen

• Missing the toxin suppression rationale loses marks

❌ Delaying surgery for imaging

• "Door to OR" not "door to CT" in unstable/obvious cases

❌ Not mentioning planned re-look surgery

• Single debridement is almost never sufficient

❌ Forgetting to consider colostomy

• Essential for colorectal source with faecal contamination

❌ Saying testes need to be removed

• Testes are almost always spared due to separate blood supply

High-Yield Facts for Exams

1. Mortality increases 7.6% for each hour delay in antibiotics in sepsis [86]
2. LRINEC score ≥6 suggests necrotising fasciitis, but low score doesn't exclude it [42]
3. FGSI score > 9 associated with 75% mortality [48]
4. Anatomical spread: Dartos → Colles' → Scarpa's fascia
5. Microbiology: Polymicrobial (average 4-5 organisms), most common E. coli and Bacteroides [27]
6. Triple antibiotic therapy: Carbapenem + Anti-MRSA + Clindamycin
7. Colostomy indicated for colorectal source with faecal contamination or sphincter damage

---

16. Related Conditions

Meleney's Gangrene (Synergistic Necrotising Cellulitis)

• Similar pathophysiology to Fournier's but affects abdominal wall
• Typically post-operative (laparotomy, appendectomy)
• Synergistic infection (Streptococcus + Staphylococcus)
• Management identical: radical debridement [87]

Necrotising Fasciitis (General)

• Can affect any body site (limbs most common)
• Type I: Polymicrobial (similar to Fournier's)
• Type II: Monomicrobial (Group A Streptococcus - "flesh-eating bacteria")
• Type II more aggressive, higher toxin production
• Management principles same: antibiotics + emergency debridement [10]

Gas Gangrene (Clostridial Myonecrosis)

• Caused by Clostridium perfringens (Gram-positive anaerobe)
• Affects muscle (not just fascia)
• Profound systemic toxicity
• Massive gas production (crepitus universal)
• Requires debridement + high-dose penicillin + clindamycin
• Hyperbaric oxygen more established role [88]

---

17. References

Primary Sources

1. Bonkat G, et al. EAU Guidelines on Urological Infections. European Association of Urology. 2023.

2. Fournier JA. Gangrène foudroyante de la verge. Semaine Medicale. 1883;3:345-347.

3. Eke N. Fournier's gangrene: a review of 1726 cases. British Journal of Surgery. 2000;87(6):718-728. doi:10.1046/j.1365-2168.2000.01497.x

4. Mallikarjuna MN, et al. Fournier's gangrene: current practices. ISRN Surgery. 2012;2012:942437. doi:10.5402/2012/942437

5. Shyam DC, Rapsang AG. Fournier's gangrene. Surgeon. 2013;11(4):222-232. doi:10.1016/j.surge.2013.02.001

6. Moore KL, Dalley AF. Clinically Oriented Anatomy. 7th ed. Lippincott Williams & Wilkins. 2013.

7. Elliott DC, et al. Necrotizing soft tissue infections: risk factors for mortality and strategies for management. Annals of Surgery. 1996;224(5):672-683. doi:10.1097/00000658-199611000-00011

8. Singh A, et al. Fournier's gangrene: a clinical review. Urology Annals. 2016;8(4):453-458. doi:10.4103/0974-7796.192102

9. Sorensen MD, et al. Fournier's gangrene: population-based epidemiology and outcomes. Journal of Urology. 2009;181(5):2120-2126. doi:10.1016/j.juro.2009.01.034

10. Stevens DL, Bryant AE. Necrotizing soft-tissue infections. New England Journal of Medicine. 2017;377(23):2253-2265. doi:10.1056/NEJMra1600673

11. Wall DB, et al. Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. American Journal of Surgery. 2000;179(1):17-21. doi:10.1016/s0002-9610(99)00259-3

12. Burner E, et al. Inadequate sensitivity of laboratory risk indicator to rule out necrotizing fasciitis in the emergency department. Western Journal of Emergency Medicine. 2016;17(3):333-336. doi:10.5811/westjem.2016.2.29069

13. Bjurlin MA, et al. Genitourinary infections with mortality in the U.S.: analysis of a national database. Journal of Urology. 2013;190(2):552-558. doi:10.1016/j.juro.2013.02.006

14. Yeniyol CO, et al. Fournier's gangrene: experience with 25 patients and use of Fournier's gangrene severity index score. Urology. 2004;64(2):218-222. doi:10.1016/j.urology.2004.03.049

15. Yanar H, et al. Fournier's gangrene: an analysis of 80 patients and a novel scoring system. Techniques in Coloproctology. 2008;12(2):119-123. doi:10.1007/s10151-008-0400-4

16. Thwaini A, et al. Fournier's gangrene and its emergency management. Postgraduate Medical Journal. 2006;82(970):516-519. doi:10.1136/pgmj.2005.042069

17. Sorensen MD, et al. Fournier's gangrene: management and mortality predictors in a population based study. Journal of Urology. 2009;182(6):2742-2747. doi:10.1016/j.juro.2009.08.050

18. Smith GL, et al. Risk factors associated with mortality in Fournier's gangrene. Urology. 2009;74(6):1274-1279. doi:10.1016/j.urology.2009.06.055

19. Czymek R, et al. Fournier's gangrene: is the female gender a risk factor? Langenbeck's Archives of Surgery. 2010;395(2):173-180. doi:10.1007/s00423-009-0530-6

20. Kuzaka B, et al. Fournier's gangrene: clinical presentation of 13 cases. Medical Science Monitor. 2009;15(11):CS132-138.

21. Norton KS, et al. Management of Fournier's gangrene: an eleven year retrospective analysis of early recognition, diagnosis, and treatment. American Surgeon. 2002;68(8):709-713.

22. Agboola JO, et al. Fournier's gangrene in HIV patients. African Journal of Urology. 2014;20(1):21-24. doi:10.1016/j.afju.2013.10.001

23. Ersay AR, et al. Factors affecting mortality in Fournier's gangrene: analysis of 20 cases. International Urology and Nephrology. 2007;39(4):1055-1058. doi:10.1007/s11255-006-9160-4

24. Basoglu M, et al. Management of Fournier's gangrene: review of 45 cases. Surgery Today. 2007;37(7):558-563. doi:10.1007/s00595-006-3497-4

25. Palmer LS, et al. Pediatric urological reconstruction following Fournier's gangrene. Journal of Urology. 1998;160(3):1040-1042.

26. El-Shahat AA, et al. Predictors of outcome in Fournier's gangrene. Arab Journal of Urology. 2015;13(1):24-28. doi:10.1016/j.aju.2014.07.002

27. Brook I, Frazier EH. Clinical and microbiological features of necrotizing fasciitis. Journal of Clinical Microbiology. 1995;33(9):2382-2387. doi:10.1128/jcm.33.9.2382-2387.1995

28. Chawla SN, et al. The severity index: a useful guide to treatment of Fournier's gangrene. British Journal of Urology. 1999;83(9):985-989. doi:10.1046/j.1464-410x.1999.00019.x

29. Hakkarainen TW, et al. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Current Problems in Surgery. 2014;51(8):344-362. doi:10.1067/j.cpsurg.2014.06.001

30. Laucks SS. Fournier's gangrene. Surgical Clinics of North America. 1994;74(6):1339-1352.

31. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clinical Infectious Diseases. 2007;44(5):705-710. doi:10.1086/511638

32. Sarani B, et al. Necrotizing fasciitis: current concepts and review of the literature. Journal of the American College of Surgeons. 2009;208(2):279-288. doi:10.1016/j.jamcollsurg.2008.10.032

33. Tilley DO, et al. Necrotizing soft tissue infections: the introduction of the toxic shock syndrome and increased mortality. Plastic and Reconstructive Surgery. 2008;121(4):1205-1215. doi:10.1097/01.prs.0000305535.75816.68

34. Verma S, et al. Fournier's gangrene in females: experience from a tertiary care centre. Journal of Clinical and Diagnostic Research. 2015;9(12):PC06-PC08. doi:10.7860/JCDR/2015/16134.6967

35. Morpurgo E, Galandiuk S. Fournier's gangrene. Surgical Clinics of North America. 2002;82(6):1213-1224. doi:10.1016/s0039-6109(02)00058-0

36. Taviloglu K, Yanar H. Necrotizing fasciitis: strategies for diagnosis and management. World Journal of Emergency Surgery. 2007;2:19. doi:10.1186/1749-7922-2-19

37. Levenson RB, et al. Fournier gangrene: role of imaging. Radiographics. 2008;28(2):519-528. doi:10.1148/rg.282075048

38. Trojian TH, et al. Epididymitis and orchitis: an overview. American Family Physician. 2009;79(7):583-587.

39. Sharp VJ, et al. Testicular torsion: diagnosis, evaluation, and management. American Family Physician. 2013;88(12):835-840.

40. Fitzgibbons RJ, et al. Groin hernia in adults. New England Journal of Medicine. 2015;372(8):756-763. doi:10.1056/NEJMcp1404068

41. Steele SR, et al. Practice parameters for the management of perianal abscess and fistula-in-ano. Diseases of the Colon & Rectum. 2011;54(12):1465-1474. doi:10.1097/DCR.0b013e31823122b3

42. Wong CH, et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Critical Care Medicine. 2004;32(7):1535-1541. doi:10.1097/01.ccm.0000129486.35458.7d

43. Fernando SM, et al. Necrotizing soft tissue infection: diagnostic accuracy of physical examination, imaging, and LRINEC score: a systematic review and meta-analysis. Annals of Surgery. 2019;269(1):58-65. doi:10.1097/SLA.0000000000002774

44. Roche JJ, et al. Plain radiography in the diagnosis of necrotizing fasciitis. Clinical Radiology. 1998;53(7):541-542. doi:10.1016/s0009-9260(98)80197-1

45. Kane CJ, et al. Ultrasound in the diagnosis and management of Fournier's gangrene. Urology. 1996;48(5):719-723. doi:10.1016/s0090-4295(96)00364-7

46. Wysoki MG, et al. Urology emergencies in the cancer patient. Seminars in Oncology. 2000;27(3):284-298.

47. Wysoki MG, et al. Role of CT in diagnosis of Fournier gangrene. Radiology. 1997;203(P):336.

48. Laor E, et al. Outcome prediction in patients with Fournier's gangrene. Journal of Urology. 1995;154(1):89-92. doi:10.1016/s0022-5347(01)67236-7

49. Tuncel A, et al. Fournier's gangrene: Three years of experience with 20 patients and validity of the Fournier's gangrene severity index score. European Urology. 2006;50(4):838-843. doi:10.1016/j.eururo.2006.01.030

50. Yilmazlar T, et al. Fournier's gangrene: review of 120 patients and predictors of mortality. ANZ Journal of Surgery. 2014;84(4):255-259. doi:10.1111/ans.12695

51. Evans L, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Critical Care Medicine. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337

52. Edino ST, et al. Fournier's gangrene: analysis of 20 cases in Zaria. Nigerian Journal of Medicine. 2004;13(3):280-283.

53. Van den Berghe G, et al. Intensive insulin therapy in critically ill patients. New England Journal of Medicine. 2001;345(19):1359-1367. doi:10.1056/NEJMoa011300

54. Kumar A, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine. 2006;34(6):1589-1596. doi:10.1097/01.CCM.0000217961.75225.E9

55. Dworkin MS, et al. Risk factors for death from necrotizing fasciitis: a comparative analysis of methicillin-resistant and methicillin-susceptible Staphylococcus aureus infections. Infectious Diseases in Clinical Practice. 2009;17(1):17-21.

56. Zimbelman J, et al. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatric Infectious Disease Journal. 1999;18(12):1096-1100. doi:10.1097/00006454-199912000-00014

57. Stevens DL, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. Journal of Infectious Diseases. 2007;195(2):202-211. doi:10.1086/510396

58. Malic S, et al. Detection and identification of specific bacteria in wound biofilms using peptide nucleic acid fluorescent in situ hybridization (PNA FISH). Microbiology. 2009;155(Pt 8):2603-2611. doi:10.1099/mic.0.028712-0

59. Riseman JA, et al. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery. 1990;108(5):847-850.

60. Kobayashi L, et al. Necrotizing soft tissue infections: delayed surgical treatment is associated with increased number of surgical debridements and morbidity. Journal of Trauma. 2011;71(5):1400-1405. doi:10.1097/TA.0b013e31820f802f

61. Kearns RJ, et al. Intensive care admission for patients with necrotizing fasciitis: a UK national survey. Anaesthesia. 2010;65(11):1094-1100. doi:10.1111/j.1365-2044.2010.06517.x

62. Norton KS, et al. Management of Fournier's gangrene: an eleven year retrospective analysis of early recognition, diagnosis, and treatment. American Surgeon. 2002;68(8):709-713.

63. Tuncel A, et al. Fournier's gangrene in the elderly: a plea for early recognition and aggressive treatment. International Urology and Nephrology. 2009;41(3):547-552. doi:10.1007/s11255-008-9490-0

64. Martindale RG, et al. Nutrition support in necrotizing soft tissue infections. Surgical Infections. 2009;10(1):87-91. doi:10.1089/sur.2008.068

65. Erol B, et al. The effect of initial number of debridement on mortality in Fournier's gangrene. Turkish Journal of Urology. 2010;36(4):354-358.

66. Czymek R, et al. Fournier's gangrene: vacuum-assisted closure versus conventional dressings. American Journal of Surgery. 2009;197(2):168-176. doi:10.1016/j.amjsurg.2008.07.053

67. Ozturk E, et al. Surgical site infection and antibiotic prophylaxis in Fournier's gangrene. Surgical Infections. 2006;7(6):555-560. doi:10.1089/sur.2006.7.555

68. Koukouras D, et al. Fournier's gangrene: a urologic and surgical emergency. Surgical Practice. 2011;15(2):50-58. doi:10.1111/j.1744-1633.2011.00561.x

69. Shaw JJ, Psoinos C, et al. Not just full of hot air: hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections. Surgical Infections. 2014;15(3):328-335. doi:10.1089/sur.2012.135

70. Chennamsetty A, et al. Contemporary diagnosis and management of Fournier's gangrene. Therapeutic Advances in Urology. 2015;7(4):203-215. doi:10.1177/1756287215584740

71. Escobar SJ, et al. Hyperbaric oxygen therapy in necrotizing soft tissue infections: a critical review of the literature. American Surgeon. 2005;71(2):144-151.

72. Darenberg J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clinical Infectious Diseases. 2003;37(3):333-340. doi:10.1086/376630

73. Russell JA, et al. Vasopressor therapy in critically ill patients with shock. Intensive Care Medicine. 2019;45(11):1503-1517. doi:10.1007/s00134-019-05801-z

74. Bellomo R, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care. 2004;8(4):R204-212. doi:10.1186/cc2872

75. Levi M, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Journal of Haematology. 2009;145(1):24-33. doi:10.1111/j.1365-2141.2009.07600.x

76. Fan E, et al. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA. 2018;319(7):698-710. doi:10.1001/jama.2017.21907

77. Mouraviev V, et al. Urethral stricture in the setting of necrotizing fasciitis: a therapeutic challenge. Urology. 2005;65(2):388. doi:10.1016/j.urology.2004.09.055

78. Altunoluk B, et al. Quality of life and sexual functioning in patients with Fournier's gangrene. Urology Journal. 2011;8(1):49-54.

79. Khandelwal C, et al. Fournier's gangrene: the psychological consequences. BJU International. 2008;101(8):965-966. doi:10.1111/j.1464-410X.2008.07431.x

80. Safioleas M, et al. Fournier's gangrene: exists and it is still lethal. International Urology and Nephrology. 2006;38(3-4):653-657. doi:10.1007/s11255-006-0095-3

81. Ferreira PC, et al. Fournier's gangrene: a review of 34 cases. ANZ Journal of Surgery. 2007;77(3):150-153. doi:10.1111/j.1445-2197.2006.03999.x

82. Altunoluk B, et al. Fournier's gangrene: conventional dressings versus vacuum-assisted closure. ANZ Journal of Surgery. 2012;82(4):218-224. doi:10.1111/j.1445-2197.2012.06006.x

83. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2021;44(Suppl 1):S1-S232. doi:10.2337/dc21-Sint

84. Pizzorno R, et al. Hyperbaric oxygen therapy in the treatment of Fournier's disease in 11 male patients. Journal of Urology. 1997;158(3 Pt 1):837-840. doi:10.1016/s0022-5347(01)64339-2

85. Stevens DL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2014;59(2):e10-52. doi:10.1093/cid/ciu296

86. Ferrer R, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Critical Care Medicine. 2014;42(8):1749-1755. doi:10.1097/CCM.0000000000000330

87. Meleney FL. Hemolytic streptococcus gangrene. Archives of Surgery. 1924;9(2):317-364. doi:10.1001/archsurg.1924.01120080083004

88. Hart GB, et al. Gas gangrene. Journal of Trauma. 1983;23(11):991-1000.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines.